Children as young as two with either sickle cell disease or thalassemia are now eligible for the gene therapy.
The industry looks set to continue a preference for European outsourcing facilities as national tax systems exert influence.
Ipsen’s Memo acquisition is the second the former has signed this week alone, following its blockbuster Kartos buyout on 29 June.
Our editorial team delve into the key takeaways from the 2026 HLTH Europe conference and the 2026 BIO International Convention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results